US5679399A
(en)
|
1987-07-17 |
1997-10-21 |
Bio Barrier, Inc. |
Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
|
US5549924A
(en)
|
1987-07-17 |
1996-08-27 |
Robin Renee Thill Shlenker |
Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
|
US5314696A
(en)
*
|
1991-06-27 |
1994-05-24 |
Paulos Manley A |
Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
|
WO1996010996A1
(en)
*
|
1993-07-21 |
1996-04-18 |
The University Of Kentucky Research Foundation |
A multicompartment hard capsule with control release properties
|
US5397574A
(en)
*
|
1993-10-04 |
1995-03-14 |
Andrx Pharmaceuticals, Inc. |
Controlled release potassium dosage form
|
FR2723536A1
(fr)
*
|
1994-08-11 |
1996-02-16 |
Seth Pawan |
Composition permettant une liberation selective d'un principe actif
|
US5567441A
(en)
*
|
1995-03-24 |
1996-10-22 |
Andrx Pharmaceuticals Inc. |
Diltiazem controlled release formulation
|
US20060068018A1
(en)
*
|
1996-03-25 |
2006-03-30 |
Wyeth |
Extended release formulation
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
WO1998029095A2
(en)
*
|
1997-01-03 |
1998-07-09 |
Elan Corporation, Plc |
Sustained release cisapride mini-tablet formulation
|
PL193282B1
(pl)
*
|
1997-01-14 |
2007-01-31 |
Lohmann Therapie Syst Lts |
System terapeutyczny do kontrolowanego uwalniania substancji czynnych w przewodzie żołądkowo-jelitowym
|
US5788987A
(en)
*
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
US5840329A
(en)
*
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
MY125849A
(en)
*
|
1997-07-25 |
2006-08-30 |
Alza Corp |
Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
|
PL203733B1
(pl)
*
|
1997-10-09 |
2009-11-30 |
Dexcel Pharma Technologies Ltd |
Układ do natychmiastowego uwalniania pożądanego środka miejscowo w przewodzie żołądkowo-jelitowym zwierzęcia i zastosowanie
|
US6607751B1
(en)
*
|
1997-10-10 |
2003-08-19 |
Intellipharamaceutics Corp. |
Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
US5916595A
(en)
*
|
1997-12-12 |
1999-06-29 |
Andrx Pharmaceutials, Inc. |
HMG co-reductase inhibitor
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
US6372254B1
(en)
|
1998-04-02 |
2002-04-16 |
Impax Pharmaceuticals Inc. |
Press coated, pulsatile drug delivery system suitable for oral administration
|
ATE321538T1
(de)
*
|
1998-08-12 |
2006-04-15 |
Altana Pharma Ag |
Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
|
US6531152B1
(en)
|
1998-09-30 |
2003-03-11 |
Dexcel Pharma Technologies Ltd. |
Immediate release gastrointestinal drug delivery system
|
US6322819B1
(en)
|
1998-10-21 |
2001-11-27 |
Shire Laboratories, Inc. |
Oral pulsed dose drug delivery system
|
US20090297597A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Gary Liversidge |
Modified Release Ticlopidine Compositions
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
EP2020229A1
(de)
*
|
1998-11-02 |
2009-02-04 |
Elan Pharma International Limited |
Mehrpartikelmodifizierte Freisetzungszusammensetzung
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
US20080118556A1
(en)
*
|
1998-11-02 |
2008-05-22 |
Elan Corporation, Plc |
Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
EP1133230A4
(de)
|
1998-11-23 |
2004-05-26 |
Bonnie M Davis |
Dosisformulierungen für acetylcholinesterase-inhibitoren
|
US6210716B1
(en)
*
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US20030170181A1
(en)
*
|
1999-04-06 |
2003-09-11 |
Midha Kamal K. |
Method for preventing abuse of methylphenidate
|
US6217904B1
(en)
*
|
1999-04-06 |
2001-04-17 |
Pharmaquest Ltd. |
Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant
|
US6632451B2
(en)
|
1999-06-04 |
2003-10-14 |
Dexcel Pharma Technologies Ltd. |
Delayed total release two pulse gastrointestinal drug delivery system
|
GB9923045D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Novartis Ag |
New oral formulations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
KR101216270B1
(ko)
|
1999-10-29 |
2012-12-31 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
ATE273868T1
(de)
*
|
1999-11-17 |
2004-09-15 |
Reckitt Benckiser Uk Ltd |
Spritzgegossener wasserlöslicher behälter
|
AU1556000A
(en)
*
|
1999-11-22 |
2001-06-04 |
Akzo Nobel N.V. |
Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
|
US7108866B1
(en)
|
1999-12-10 |
2006-09-19 |
Biovall Laboratories International Srl |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
CA2395231C
(en)
|
1999-12-23 |
2006-08-15 |
Pfizer Products Inc. |
Hydrogel-driven layered drug dosage form
|
US6669954B2
(en)
|
2000-01-25 |
2003-12-30 |
John R. Crison |
Controlled release of drugs
|
US6627223B2
(en)
*
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
US6669948B2
(en)
|
2000-02-24 |
2003-12-30 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6627222B2
(en)
|
2000-02-24 |
2003-09-30 |
Advancis Pharmaceutical Corp. |
Amoxicillin-dicloxacillin antibiotic composition
|
US6991807B2
(en)
*
|
2000-02-24 |
2006-01-31 |
Advancis Pharmaceutical, Corp. |
Antibiotic composition
|
AU2001239869B2
(en)
*
|
2000-02-24 |
2005-12-15 |
Shionogi, Inc. |
Antibiotic composition with inhibitor
|
US6638532B2
(en)
|
2000-02-24 |
2003-10-28 |
Advancis Pharmaceutical Corp. |
Tetracycline—doxycycline antibiotic composition
|
US6623758B2
(en)
*
|
2000-02-24 |
2003-09-23 |
Advancis Pharmaceutical Corp. |
Cephalosporin-metronidazole antibiotic composition
|
US6663891B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Erythromyacin antibiotic product, use and formulation thereof
|
US6730320B2
(en)
|
2000-02-24 |
2004-05-04 |
Advancis Pharmaceutical Corp. |
Tetracycline antibiotic product, use and formulation thereof
|
US6623757B2
(en)
|
2000-02-24 |
2003-09-23 |
Advancis Pharmaceutical Corp. |
Antibiotic composition
|
AU2001239838A1
(en)
*
|
2000-02-24 |
2001-09-03 |
Advancis Pharmaceutical Corporation |
Therapeutic product, use and formulation thereof
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6667057B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Levofloxacin antibiotic product, use and formulation thereof
|
US6610328B2
(en)
|
2000-02-24 |
2003-08-26 |
Advancis Pharmaceutical Corp. |
Amoxicillin-clarithromycin antibiotic composition
|
US7025989B2
(en)
*
|
2000-02-24 |
2006-04-11 |
Advancis Pharmaceutical Corp. |
Multiple-delayed released antibiotic product, use and formulation thereof
|
US6667042B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Fluroquinilone antibiotic product, use and formulation thereof
|
US6663890B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Metronidazole antibiotic product, use and formulation thereof
|
US6632453B2
(en)
|
2000-02-24 |
2003-10-14 |
Advancis Pharmaceutical Corp. |
Ciprofoxacin-metronidazole antibiotic composition
|
DE60128215T2
(de)
|
2000-04-20 |
2008-01-10 |
Novartis Ag |
Beschichtungszusammensetzung zur geschmacksmaskierung
|
US6551617B1
(en)
|
2000-04-20 |
2003-04-22 |
Bristol-Myers Squibb Company |
Taste masking coating composition
|
US6500457B1
(en)
|
2000-08-14 |
2002-12-31 |
Peirce Management, Llc |
Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
|
US7157095B2
(en)
*
|
2000-10-13 |
2007-01-02 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release antifungal product, use and formulation thereof
|
US7108859B2
(en)
*
|
2000-10-13 |
2006-09-19 |
Advancis Pharmaceutical Corporation |
Antineoplastic product, use and formulation thereof
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US7074417B2
(en)
*
|
2000-10-13 |
2006-07-11 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-viral product, use and formulation thereof
|
US7105174B2
(en)
*
|
2000-10-13 |
2006-09-12 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-neoplastic product, use and formulation thereof
|
CA2427815C
(en)
|
2000-10-30 |
2007-07-10 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
EP1738751B1
(de)
|
2001-01-12 |
2011-05-11 |
Sun Pharma Advanced Research Company Ltd |
System zur beabstandeten Abgabe von Arzneimitteln
|
US20020197314A1
(en)
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
MXPA03008293A
(es)
*
|
2001-03-13 |
2003-12-11 |
Penwest Pharmaceuticals Co |
Formas de dosis cronoterapeuticas.
|
US20040156900A1
(en)
*
|
2001-04-10 |
2004-08-12 |
Shanghvi Dilip Shantilal |
Time pulsed release composition
|
US6663896B1
(en)
|
2001-08-01 |
2003-12-16 |
Alvin S. Blum |
Delayed release aspirin for vascular obstruction prophylaxis
|
US9358214B2
(en)
*
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
US6500454B1
(en)
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
CA2409552A1
(en)
*
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
US6635675B2
(en)
|
2001-11-05 |
2003-10-21 |
Cypress Bioscience, Inc. |
Method of treating chronic fatigue syndrome
|
US6602911B2
(en)
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
US20050163846A1
(en)
*
|
2001-11-21 |
2005-07-28 |
Eisai Co., Ltd. |
Preparation composition containing acid-unstable physiologically active compound, and process for producing same
|
US6663888B2
(en)
*
|
2001-12-14 |
2003-12-16 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
US20050025824A1
(en)
*
|
2001-12-14 |
2005-02-03 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
KR20040073495A
(ko)
*
|
2001-12-19 |
2004-08-19 |
가부시키가이샤산와카가쿠켄큐쇼 |
방출제어형 성형품
|
EP1465591A1
(de)
*
|
2001-12-20 |
2004-10-13 |
Advancis Pharmaceutical Corporation |
Antibiotisches produkt, verwendung und formulierung davon
|
GB0130518D0
(en)
*
|
2001-12-21 |
2002-02-06 |
Univ Gent |
Pulsed bio-agent delivery systems based on degradable polymer solutions or hydrogels
|
EP1482910A1
(de)
*
|
2002-03-05 |
2004-12-08 |
Ranbaxy Laboratories, Ltd. |
Orale pharmazeutische zusammensetzung mit modifizierter freisetzung
|
WO2003075852A2
(en)
*
|
2002-03-07 |
2003-09-18 |
Advancis Pharmaceuticals Corporation |
Antibiotic composition
|
US7670612B2
(en)
|
2002-04-10 |
2010-03-02 |
Innercap Technologies, Inc. |
Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
|
US6958161B2
(en)
|
2002-04-12 |
2005-10-25 |
F H Faulding & Co Limited |
Modified release coated drug preparation
|
JP4485945B2
(ja)
*
|
2002-06-26 |
2010-06-23 |
インターシア セラピューティクス,インコーポレイティド |
浸透圧デリバリーシステムの最小服従型で、容積効率型ピストン
|
AU2003244840C1
(en)
|
2002-07-05 |
2010-03-04 |
Temrel Limited |
Controlled release composition
|
US6913768B2
(en)
*
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
CA2406592C
(en)
*
|
2002-10-04 |
2003-09-30 |
Duchesnay Inc. |
Method of preparing pharmaceutical dosage forms containing multiple active ingredients
|
BR0315731A
(pt)
*
|
2002-10-30 |
2005-09-06 |
Pharmacia Corp |
Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos
|
AU2003298658A1
(en)
|
2002-11-15 |
2004-06-15 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
US20040114368A1
(en)
*
|
2002-12-13 |
2004-06-17 |
Shyu Shing Jy |
Light device having rotatable or movable view
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
US7153526B2
(en)
*
|
2003-02-26 |
2006-12-26 |
Frank Steven R |
Treatment of gastrointestinal infections
|
US20060210633A1
(en)
*
|
2003-04-03 |
2006-09-21 |
Sun Pharmaceutical Industries Limited |
Programmed drug delivery system
|
CA2520321A1
(en)
*
|
2003-04-04 |
2004-10-14 |
Pharmacia Corporation |
Oral extended release compressed tablets of multiparticulates
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
EP1648418A4
(de)
|
2003-07-21 |
2011-11-16 |
Middlebrook Pharmaceuticals Inc |
Antibiotisches produkt, seine verwendung und formulierung
|
CA2533292C
(en)
*
|
2003-07-21 |
2013-12-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
AU2004258949B2
(en)
|
2003-07-21 |
2011-02-10 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
JP2007502296A
(ja)
|
2003-08-11 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
ロバストペレット
|
AU2004264356B2
(en)
|
2003-08-12 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
US8246996B2
(en)
|
2003-08-29 |
2012-08-21 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
US8460710B2
(en)
|
2003-09-15 |
2013-06-11 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
US8389008B2
(en)
*
|
2003-09-19 |
2013-03-05 |
Penwest Pharmaceuticals Co. |
Delayed release dosage forms
|
MXPA06003101A
(es)
*
|
2003-09-19 |
2006-06-20 |
Penwest Pharmaceuticals Co |
Formas de dosis cronoterapeuticas.
|
TWI372066B
(en)
*
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US7387793B2
(en)
|
2003-11-14 |
2008-06-17 |
Eurand, Inc. |
Modified release dosage forms of skeletal muscle relaxants
|
US20050142187A1
(en)
*
|
2003-12-24 |
2005-06-30 |
Treacy Donald J.Jr. |
Enhanced absorption of modified release dosage forms
|
NZ549838A
(en)
*
|
2004-03-26 |
2010-04-30 |
Eisai R&D Man Co Ltd |
Coated controlled-release preparation containing a gastric acid secretion inhibitor
|
US7404970B2
(en)
*
|
2004-04-13 |
2008-07-29 |
Konec, Inc. |
Pain relief composition, method to form same, and method to use same
|
WO2006009602A2
(en)
|
2004-06-16 |
2006-01-26 |
Tap Pharmaceutical Products, Inc. |
Multiple ppi dosage form
|
WO2006004774A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Stanford University |
Laulimalide analogues as therapeutic agents
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
EP1771158A4
(de)
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
Tablette für pulsierte abgabe
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
ES2409347T3
(es)
|
2004-10-21 |
2013-06-26 |
Aptalis Pharmatech, Inc. |
Composiciones farmacéuticas de sabor enmascarado con agentes porogénicos gastrosolubles
|
US20060121112A1
(en)
*
|
2004-12-08 |
2006-06-08 |
Elan Corporation, Plc |
Topiramate pharmaceutical composition
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
AU2006235483B2
(en)
*
|
2005-04-12 |
2010-11-25 |
Elan Pharma International Limited |
Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
EP1933852B1
(de)
|
2005-09-27 |
2018-12-19 |
TissueTech, Inc. |
Amnion-zubereitungen und gereinigte zusammensetzungen und anwendungsverfahren
|
US8187639B2
(en)
*
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
US7994220B2
(en)
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
EP1930030A1
(de)
*
|
2005-09-29 |
2008-06-11 |
Eisai R&D Management Co., Ltd. |
Puls-präparat mit verbesserten zerfallseigenschaften in vivo
|
KR20080080094A
(ko)
*
|
2005-10-14 |
2008-09-02 |
하. 룬트벡 아크티에 셀스카브 |
에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
|
AU2006304889A1
(en)
*
|
2005-10-14 |
2007-04-26 |
H. Lundbeck A/S |
Stable pharmaceutical formulations containing escitalopram and bupropion
|
US8440695B2
(en)
*
|
2005-11-09 |
2013-05-14 |
St Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
WO2007062266A2
(en)
|
2005-11-28 |
2007-05-31 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
BRPI0620236A2
(pt)
*
|
2005-12-23 |
2011-11-01 |
Lek Pharmaceuticals |
péletes dilacerantes
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US20090069275A1
(en)
*
|
2006-02-17 |
2009-03-12 |
Rocca Jose G |
Low flush niacin formulation
|
CN104825397A
(zh)
|
2006-04-03 |
2015-08-12 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
NZ572003A
(en)
|
2006-05-30 |
2010-07-30 |
Intarcia Therapeutics Inc |
Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
|
WO2008021133A2
(en)
|
2006-08-09 |
2008-02-21 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies
|
EP2056818B1
(de)
|
2006-08-11 |
2011-05-25 |
The Johns Hopkins University |
Zusammensetzungen und verfahren für nervenschutz
|
US8124598B2
(en)
*
|
2006-09-14 |
2012-02-28 |
Sharon Sageman |
7-keto DHEA for psychiatric use
|
MX347525B
(es)
|
2006-09-22 |
2017-04-27 |
Pharmacyclics Llc |
Inhibidores de tirosina cinasa de bruton.
|
WO2008062320A2
(en)
*
|
2006-10-06 |
2008-05-29 |
Eisai R&D Management Co., Ltd |
Extended release formulations of a proton pump inhibitor
|
KR20090091321A
(ko)
|
2006-11-28 |
2009-08-27 |
마리누스 파마슈티컬스 |
나노입자 제형, 이의 제조방법 및 이의 용도
|
US8795721B2
(en)
*
|
2006-12-18 |
2014-08-05 |
Eatlittle Inc. |
Device for delivery of a substance
|
PL2099442T3
(pl)
|
2006-12-26 |
2015-04-30 |
Pharmacyclics Inc |
Sposób stosowania inhibitorów deacetylazy histonów i monitoringu biomarkerów w terapii skojarzonej
|
US20080187579A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Pavan Bhat |
Extended-release dosage form
|
NZ580447A
(en)
|
2007-04-23 |
2011-06-30 |
Intarcia Therapeutics Inc |
Suspension formulations of insulinotropic peptides and uses thereof
|
US20100160274A1
(en)
*
|
2007-09-07 |
2010-06-24 |
Sharon Sageman |
7-KETO DHEA for Psychiatric Use
|
JP5411141B2
(ja)
|
2007-09-10 |
2014-02-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
MY153062A
(en)
*
|
2007-10-12 |
2014-12-31 |
Takeda Pharmaceuticals Usa Inc |
Methods of treating gastrointestinal disorders independent of the intake of food
|
US8343140B2
(en)
|
2008-02-13 |
2013-01-01 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
FR2930147B1
(fr)
*
|
2008-04-18 |
2013-02-08 |
Flamel Tech Sa |
Forme orale solide dotee d'un double profil de liberation
|
AU2009279372A1
(en)
|
2008-08-06 |
2010-02-11 |
Gosforth Centre (Holdings) Pty Ltd |
Compositions and methods for treating psychiatric disorders
|
MX2011002149A
(es)
|
2008-08-27 |
2011-04-05 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
AU2009311877C1
(en)
*
|
2008-11-07 |
2013-08-15 |
Samyang Holdings Corporation |
Pharmaceutical composition for release control of methylphenidate
|
US20100158905A1
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Combination therapy of arthritis with tranilast
|
EP2405901A1
(de)
|
2009-03-09 |
2012-01-18 |
Council of Scientific & Industrial Research |
Zusammensetzung eines therapeutischen mittels mit gepulster freisetzung
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
US9175066B2
(en)
|
2009-04-24 |
2015-11-03 |
Tissuetech, Inc. |
Compositions containing HC-HA complex and methods of use thereof
|
US8808257B2
(en)
|
2009-08-31 |
2014-08-19 |
Johnson & Johnson Vision Care, Inc. |
Methods and apparatus for pulsatile release of medicaments from a punctal plug
|
NZ624569A
(en)
|
2009-09-28 |
2016-01-29 |
Intarcia Therapeutics Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
EP2506836B1
(de)
|
2009-12-02 |
2018-02-14 |
Adare Pharmaceuticals S.R.L. |
Fexofenadin-mikrokapseln und zusammensetzungen damit
|
US20130030237A1
(en)
|
2010-04-15 |
2013-01-31 |
Charles Theuer |
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
EP2563759B1
(de)
|
2010-04-27 |
2022-04-06 |
Calcimedica, Inc. |
Verbindungen als modulatoren von intrazellulärem calcium
|
EP2568999B1
(de)
|
2010-05-11 |
2018-07-11 |
Mallinckrodt Ard Ip Limited |
Acth zur behandlung von amyotropher lateralsklerose
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US8796416B1
(en)
|
2010-10-25 |
2014-08-05 |
Questcor Pharmaceuticals, Inc |
ACTH prophylactic treatment of renal disorders
|
GB201100786D0
(en)
|
2011-01-18 |
2011-03-02 |
Ems Sa |
Pharmaceutical compositions of immunosuppressants
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
US9526770B2
(en)
|
2011-04-28 |
2016-12-27 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
MX353623B
(es)
|
2011-05-13 |
2018-01-22 |
Eb Ip Hybritabs B V |
Sistema de suministro de farmaco.
|
EP2717888B1
(de)
|
2011-06-10 |
2020-09-09 |
Tissuetech, Inc. |
Verfahren zur verarbeitung fötaler gewebesubstrate
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
ES2627820T3
(es)
|
2011-09-13 |
2017-07-31 |
Pharmacyclics, Inc. |
Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas
|
EP2586429A1
(de)
|
2011-10-26 |
2013-05-01 |
Freund Pharmatec Ltd. |
Arzneimittelabgabevorrichtung mit mehreren Einheiten für pulsierende oder verzögerte Freisetzung
|
WO2013080198A1
(en)
*
|
2011-11-30 |
2013-06-06 |
D.E.S. Diagnostics Ltd |
Method for quick assessment of osmolarity
|
CN104185420B
(zh)
|
2011-11-30 |
2017-06-09 |
埃默里大学 |
用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
|
WO2013080196A1
(en)
*
|
2011-11-30 |
2013-06-06 |
D.E.S. Diagnostics Ltd. |
Dry eye diagnostic
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
CN104136004B
(zh)
|
2012-02-22 |
2018-03-06 |
达切斯内公司 |
多西拉敏和吡哆醇和/或其代谢物或盐的制剂
|
EP3838293A1
(de)
|
2012-07-11 |
2021-06-23 |
Tissuetech, Inc. |
Zusammensetzungen mit hc-ha/ptx3-komplexen und verfahren zur verwendung davon
|
WO2014052914A1
(en)
|
2012-09-28 |
2014-04-03 |
University Of Washington Through Its Center For Commercialization |
Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
ES2672419T3
(es)
*
|
2012-11-19 |
2018-06-14 |
Follmann Gmbh & Co. Kg |
Microcápsulas con núcleo/corteza estables que se abren térmicamente
|
US20150335571A1
(en)
*
|
2013-01-02 |
2015-11-26 |
Eatlittle Inc. |
Pseudobezoar-Based Intraluminal Gastrointestinal Transplant
|
GB201303781D0
(en)
|
2013-03-04 |
2013-04-17 |
Gauthier Pierre Pascal |
Oral timer device and method of using same
|
US10232018B2
(en)
|
2013-03-14 |
2019-03-19 |
Mallinckrodt Ard Ip Limited |
ACTH for treatment of acute respiratory distress syndrome
|
KR102242391B1
(ko)
|
2013-07-22 |
2021-04-21 |
듀체스나이 아이엔씨 |
오심 및 구토의 관리용 조성물
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CA2930228A1
(en)
|
2013-11-11 |
2015-05-14 |
Limoxifen B.V. |
Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions
|
WO2015073736A1
(en)
|
2013-11-13 |
2015-05-21 |
Arbor Pharmaceuticals, Llc |
Methods and compositions for treating adhd
|
EP3077388A1
(de)
|
2013-12-05 |
2016-10-12 |
Pharmacyclics, LLC |
Hemmer der bruton-tyrosinkinase
|
WO2015156922A1
(en)
*
|
2014-04-08 |
2015-10-15 |
Dow Global Technologies Llc |
Dispersion comprising an esterified cellulose ether
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
TW201618783A
(zh)
|
2014-08-07 |
2016-06-01 |
艾森塔製藥公司 |
以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
CA2936746C
(en)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
US10174275B2
(en)
|
2015-01-30 |
2019-01-08 |
Follmann Gmbh & Co. Kg |
Thermally opening stable core/shell microcapsules
|
EP3253766B1
(de)
|
2015-02-06 |
2019-09-04 |
University of Washington |
Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
AU2016225000B2
(en)
|
2015-02-27 |
2021-04-01 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
ES2761616T3
(es)
|
2015-05-01 |
2020-05-20 |
Diagnostear Ltd |
Método para medir los componentes lagrimales en una muestra lagrimal
|
TWI720984B
(zh)
|
2015-05-20 |
2021-03-11 |
美商帝聖工業公司 |
用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
|
MX2017015504A
(es)
|
2015-06-03 |
2018-05-15 |
Intarcia Therapeutics Inc |
Sistemas de colocacion y remoción de implante.
|
US20180362974A1
(en)
|
2015-07-02 |
2018-12-20 |
University Of Louisville Research Foundation, Inc. |
EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
|
AU2016374497B2
(en)
|
2015-12-16 |
2022-03-10 |
The Walter And Eliza Hall Institute Of Medical Research |
Inhibition of cytokine-induced SH2 protein in NK cells
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
SG11201810102SA
(en)
|
2016-05-16 |
2018-12-28 |
Intarcia Therapeutics Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
CA3025268A1
(en)
|
2016-05-25 |
2017-11-30 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
GB2551980A
(en)
*
|
2016-06-30 |
2018-01-10 |
Commw Scient Ind Res Org |
Method and system for low level metal analysis of mineral samples
|
BR112019002538A2
(pt)
|
2016-08-11 |
2019-05-21 |
Ovid Therapeutics Inc. |
uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
|
CN109843868A
(zh)
|
2016-08-26 |
2019-06-04 |
科泰纳制药公司 |
Olig2活性的抑制
|
IL307966A
(en)
|
2017-01-03 |
2023-12-01 |
Intarcia Therapeutics Inc |
Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
WO2019039937A1
(en)
|
2017-08-21 |
2019-02-28 |
Stichting Vumc |
POLYTHERAPY FOR THE TREATMENT OF CANCER
|
CN112739345A
(zh)
|
2017-11-06 |
2021-04-30 |
斯奈普生物公司 |
Pim激酶抑制剂组合物,方法和其用途
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
USD933219S1
(en)
|
2018-07-13 |
2021-10-12 |
Intarcia Therapeutics, Inc. |
Implant removal tool and assembly
|
TW202019887A
(zh)
|
2018-07-27 |
2020-06-01 |
美商同心止痛劑股份有限公司 |
酚系trpv1促效劑之聚乙二醇化前藥
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
AU2019417833A1
(en)
|
2018-12-31 |
2021-06-24 |
Biomea Fusion, Inc. |
Irreversible inhibitors of menin-MLL interaction
|
WO2020190890A1
(en)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
WO2021026124A1
(en)
|
2019-08-05 |
2021-02-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treatment of status epilepticus
|
WO2021113834A1
(en)
|
2019-12-06 |
2021-06-10 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating tuberous sclerosis complex
|
EP4263542A1
(de)
|
2020-12-16 |
2023-10-25 |
Biomea Fusion, Inc. |
Kondensierte pyrimidinverbindungen als inhibitoren der menin-mll-interaktion
|
CA3204457A1
(en)
|
2021-01-06 |
2022-07-14 |
Ben SESSA |
Mdma in the treatment of alcohol use disorder
|
WO2022238507A1
(en)
|
2021-05-11 |
2022-11-17 |
Awakn Ls Europe Holdings Limited |
Therapeutic aminoindane compounds and compositions
|
US20230120115A1
(en)
|
2021-08-11 |
2023-04-20 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
TW202340177A
(zh)
|
2021-12-30 |
2023-10-16 |
美商拜歐米富士恩股份有限公司 |
作為 flt3抑制劑之吡嗪化合物
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|